Editas Medicine, Inc. (0IFK.L)
USD 0.98
(-6.41%)
USD 0.98
(-6.41%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 247.3 Million USD | -1.8% |
| 2022 | 245.66 Million USD | 12.33% |
| 2021 | 218.69 Million USD | -3.05% |
| 2020 | 225.57 Million USD | 39.71% |
| 2019 | 161.45 Million USD | 10.84% |
| 2018 | 145.66 Million USD | 8.98% |
| 2017 | 133.66 Million USD | 29.47% |
| 2016 | 103.24 Million USD | 179.48% |
| 2015 | 36.94 Million USD | 190.35% |
| 2014 | 12.72 Million USD | 245.36% |
| 2013 | 3.68 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 66.71 Million USD | -19.17% |
| 2024 Q2 | 70.99 Million USD | 6.41% |
| 2024 Q3 | 65.72 Million USD | -7.42% |
| 2023 Q4 | 82.54 Million USD | 48.73% |
| 2023 FY | 241.24 Million USD | -1.8% |
| 2023 Q1 | 60.81 Million USD | -13.1% |
| 2023 Q2 | 46.98 Million USD | -22.74% |
| 2023 Q3 | 55.49 Million USD | 18.13% |
| 2022 Q2 | 60.59 Million USD | 5.35% |
| 2022 FY | 245.66 Million USD | 12.33% |
| 2022 Q1 | 57.52 Million USD | 6.37% |
| 2022 Q4 | 69.98 Million USD | 21.58% |
| 2022 Q3 | 57.56 Million USD | -5.01% |
| 2021 Q4 | 54.07 Million USD | 18.98% |
| 2021 Q1 | 63.38 Million USD | -18.0% |
| 2021 Q2 | 55.78 Million USD | -11.99% |
| 2021 Q3 | 45.45 Million USD | -18.52% |
| 2021 FY | 218.69 Million USD | -3.05% |
| 2020 Q1 | 52.33 Million USD | 1.22% |
| 2020 FY | 225.57 Million USD | 39.71% |
| 2020 Q4 | 77.29 Million USD | 43.53% |
| 2020 Q3 | 53.85 Million USD | 27.95% |
| 2020 Q2 | 42.08 Million USD | -19.59% |
| 2019 Q3 | 38.43 Million USD | 1.2% |
| 2019 FY | 161.45 Million USD | 10.84% |
| 2019 Q4 | 51.7 Million USD | 34.52% |
| 2019 Q2 | 37.97 Million USD | 13.94% |
| 2019 Q1 | 33.33 Million USD | 2.96% |
| 2018 Q3 | 30.77 Million USD | -34.56% |
| 2018 Q4 | 32.37 Million USD | 5.18% |
| 2018 FY | 145.66 Million USD | 8.98% |
| 2018 Q1 | 35.48 Million USD | -11.53% |
| 2018 Q2 | 47.02 Million USD | 32.53% |
| 2017 FY | 133.66 Million USD | 29.47% |
| 2017 Q1 | 31.3 Million USD | -21.5% |
| 2017 Q2 | 29.21 Million USD | -6.7% |
| 2017 Q3 | 33.03 Million USD | 13.07% |
| 2017 Q4 | 40.1 Million USD | 21.43% |
| 2016 Q4 | 39.88 Million USD | 80.24% |
| 2016 FY | 103.24 Million USD | 179.48% |
| 2016 Q3 | 22.12 Million USD | -2.04% |
| 2016 Q2 | 22.58 Million USD | 21.15% |
| 2016 Q1 | 18.64 Million USD | 41.62% |
| 2015 Q2 | 10.56 Million USD | 104.67% |
| 2015 Q3 | 8.05 Million USD | -23.77% |
| 2015 Q1 | 5.16 Million USD | -0.52% |
| 2015 Q4 | 13.16 Million USD | 63.5% |
| 2015 FY | 36.94 Million USD | 190.35% |
| 2014 FY | 12.72 Million USD | 245.36% |
| 2014 Q3 | 2.07 Million USD | 18.8% |
| 2014 Q4 | 5.18 Million USD | 149.54% |
| 2014 Q2 | 1.75 Million USD | 0.0% |
| 2014 Q1 | 1.75 Million USD | 0.0% |
| 2013 FY | 3.68 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 13.253% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 10.297% |
| bluebird bio, Inc. | 240.23 Million USD | -2.944% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -73.592% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 87.954% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 77.299% |
| Myriad Genetics, Inc. | 600.1 Million USD | 58.79% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 97.588% |
| Biogen Inc. | 5.2 Billion USD | 95.249% |
| Nektar Therapeutics | 190.9 Million USD | -29.544% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 39.506% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 42.172% |
| Imunon, Inc. | 21.03 Million USD | -1075.934% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 84.51% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 53.252% |
| Verastem, Inc. | 92.08 Million USD | -168.563% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.391% |
| Waters Corporation | 943.51 Million USD | 73.789% |
| Perrigo Company plc | 1.52 Billion USD | 83.82% |
| Dynavax Technologies Corporation | 219.14 Million USD | -12.849% |
| Illumina, Inc. | 3.81 Billion USD | 93.514% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1677.932% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 45.165% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -104.964% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -453.662% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 85.838% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -8.144% |
| Evolus, Inc. | 189.75 Million USD | -30.325% |
| Adicet Bio, Inc. | 152.03 Million USD | -62.659% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1936.933% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 91.216% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 9.045% |
| FibroGen, Inc. | 398.11 Million USD | 37.881% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 88.307% |
| OPKO Health, Inc. | 574.68 Million USD | 56.967% |
| Homology Medicines, Inc. | 9.87 Million USD | -2404.344% |
| Geron Corporation | 70.44 Million USD | -251.08% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 86.261% |
| Exelixis, Inc. | 1.58 Billion USD | 84.415% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -145.276% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -343.547% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 55.163% |
| Zoetis Inc. | 2.76 Billion USD | 91.056% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 48.085% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -409.884% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.821% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -531.635% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 68.278% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 81.827% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 32.909% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 17.378% |
| Blueprint Medicines Corporation | 722.86 Million USD | 65.788% |
| Insmed Incorporated | 949.26 Million USD | 73.948% |
| TG Therapeutics, Inc. | 198.47 Million USD | -24.602% |
| Incyte Corporation | 1.19 Billion USD | 79.227% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 76.312% |